We describe the development and characterization of a mouse and human epithelial cell
monolayer platform of the small and large intestines, with a broad range of potential …

Hyperphosphatemia is common in patients with chronic kidney disease and is increasingly
associated with poor clinical outcomes. Current management of hyperphosphatemia with …

The majority of patients with chronic kidney disease (CKD) receiving dialysis do not achieve
target serum phosphorus concentrations, despite treatment with phosphate binders. …

Further structure–activity relationships of a novel series of fungal efflux pump inhibitors with
respect to potentiation of the activity of fluconazole against strains of C. albicans and C. …

The absorption and disposition of the serotonin 5-HT 4 receptor agonist, naronapride (6-[(3S,4R)-4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic …

Introduction: Hyperkalemia is a common complication in patients with heart failure or
chronic kidney disease, particularly those who are taking inhibitors of the renin–angiotensin–…

Hyperkalemia is common in patients with heart failure or chronic kidney disease, particularly
those taking renin‐angiotensin‐aldosterone system inhibitors, and can cause arrhythmias …

… Andrew J King,1 Cyra Fung,1 Henry Nguyen,1 Kathy White,1 Dean Dragoli,1 Cathy Le,1
Samantha Koo-McCoy,1 Padmapriya Kumaraswamy,1 Limin He,1 Kenji Kozuka,1 Craig …

Tecarfarin is a novel compound being developed for oral anticoagulation therapy for the
prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation …

Hyperkalemia is a potentially life-threatening condition, and patients who have chronic
kidney disease, who are diabetic, or who are taking renin–angiotensin–aldosterone system …